LT3447069T - Bispecifiniai egfr/c-met antikūnai - Google Patents

Bispecifiniai egfr/c-met antikūnai

Info

Publication number
LT3447069T
LT3447069T LTEP18199421.1T LT18199421T LT3447069T LT 3447069 T LT3447069 T LT 3447069T LT 18199421 T LT18199421 T LT 18199421T LT 3447069 T LT3447069 T LT 3447069T
Authority
LT
Lithuania
Prior art keywords
met antibodies
bispecific egfr
bispecific
egfr
antibodies
Prior art date
Application number
LTEP18199421.1T
Other languages
English (en)
Inventor
Mark Chiu
Sheri MOORES
Joost Neijssen
Paul Parren
Janine Schuurman
Original Assignee
Janssen Biotech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50728148&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT3447069(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Biotech, Inc. filed Critical Janssen Biotech, Inc.
Publication of LT3447069T publication Critical patent/LT3447069T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
LTEP18199421.1T 2012-11-21 2013-11-21 Bispecifiniai egfr/c-met antikūnai LT3447069T (lt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261728912P 2012-11-21 2012-11-21
US201361782550P 2013-03-14 2013-03-14
US201361809541P 2013-04-08 2013-04-08
US201361864717P 2013-08-12 2013-08-12
US201361892797P 2013-10-18 2013-10-18

Publications (1)

Publication Number Publication Date
LT3447069T true LT3447069T (lt) 2020-12-10

Family

ID=50728148

Family Applications (3)

Application Number Title Priority Date Filing Date
LTEP18199421.1T LT3447069T (lt) 2012-11-21 2013-11-21 Bispecifiniai egfr/c-met antikūnai
LTEP13856592.4T LT2922872T (lt) 2012-11-21 2013-11-21 Bispecifiniai egfr/c-met antikūnai
LTPA2022507C LTPA2022507I1 (lt) 2012-11-21 2022-06-06

Family Applications After (2)

Application Number Title Priority Date Filing Date
LTEP13856592.4T LT2922872T (lt) 2012-11-21 2013-11-21 Bispecifiniai egfr/c-met antikūnai
LTPA2022507C LTPA2022507I1 (lt) 2012-11-21 2022-06-06

Country Status (32)

Country Link
US (3) US9593164B2 (lt)
EP (3) EP3447069B1 (lt)
JP (5) JP6423357B2 (lt)
KR (3) KR102373193B1 (lt)
CN (2) CN113201073A (lt)
AU (3) AU2013347962B2 (lt)
BR (1) BR112015011717B1 (lt)
CA (2) CA2893505C (lt)
CL (1) CL2015001356A1 (lt)
CY (2) CY1121270T1 (lt)
DK (2) DK2922872T3 (lt)
EA (1) EA031184B1 (lt)
ES (2) ES2831374T3 (lt)
FI (1) FIC20220016I1 (lt)
FR (1) FR22C1018I2 (lt)
HR (2) HRP20182128T1 (lt)
HU (3) HUE052548T2 (lt)
IL (1) IL238796B (lt)
LT (3) LT3447069T (lt)
MX (1) MX361088B (lt)
NI (1) NI201500069A (lt)
NL (1) NL301173I2 (lt)
NZ (1) NZ708352A (lt)
PE (1) PE20151181A1 (lt)
PH (1) PH12015501118B1 (lt)
PL (1) PL2922872T3 (lt)
PT (2) PT3447069T (lt)
RS (2) RS61057B1 (lt)
SG (1) SG11201503938VA (lt)
SI (2) SI3447069T1 (lt)
UA (1) UA117121C2 (lt)
WO (1) WO2014081954A1 (lt)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008234248C1 (en) 2007-03-29 2015-01-22 Genmab A/S Bispecific antibodies and methods for production thereof
DK2506871T3 (da) * 2009-11-30 2017-01-02 Janssen Biotech Inc ANTISTOF-Fc-MUTANTER MED ABLATEREDE EFFEKTORFUNKTIONER
CN107739407B (zh) * 2010-03-10 2021-07-06 根马布股份公司 抗c-MEt的单克隆抗体
MX353144B (es) * 2010-04-20 2017-12-20 Genmab As Proteinas que contienen fc de anticuerpos heterodimericos y metodos para produccion de las mismas.
AU2011257121A1 (en) 2010-05-27 2013-01-10 Genmab A/S Monoclonal antibodies against HER2
EP2771364B1 (en) 2011-10-27 2019-05-22 Genmab A/S Production of heterodimeric proteins
HUE052548T2 (hu) * 2012-11-21 2021-05-28 Janssen Biotech Inc Bispecifikus EGFR/C-MET-ellenanyagok
US9695228B2 (en) 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
BR112016008125B1 (pt) 2013-10-14 2023-11-21 Janssen Biotech, Inc. Domínio proteico isolado de fibronectina tipo iii modificado com cisteína, seu método de produção e método para produzir uma molécula isolada de de fibronectina tipo iii biespecífica modificada com cisteína
CN113425727A (zh) * 2014-02-04 2021-09-24 安斯泰来制药株式会社 以二氨基杂环甲酰胺化合物为有效成分的医药组合物
AU2015223566B2 (en) 2014-02-28 2020-10-08 Merus N.V. Antibodies that bind EGFR and ErbB3
KR102309881B1 (ko) 2014-11-21 2021-10-06 삼성전자주식회사 c-Met 및 EGFR의 이중 저해제 및 IGF-1R 저해제를 포함하는 병용 투여용 약학 조성물
WO2016090174A1 (en) * 2014-12-03 2016-06-09 Auckland Uniservices, Ltd. Kinase inhibitor prodrug for the treatment of cancer
WO2016100233A1 (en) 2014-12-15 2016-06-23 The Regents Of The University Of California Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing
CA3008162A1 (en) * 2014-12-15 2016-06-23 The Regents Of The University Of California Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20
US10865253B2 (en) 2014-12-19 2020-12-15 Genmab A/S Rodent bispecific heterodimeric proteins
CN113512122A (zh) * 2014-12-22 2021-10-19 西雅图免疫公司 双特异性四价抗体及其制造和使用方法
GB201506870D0 (en) * 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
WO2016182513A1 (en) * 2015-05-13 2016-11-17 Singapore Health Services Pte Ltd Profiling of hepatocellular carcinoma and applications thereof
NZ742290A (en) 2015-10-23 2019-11-29 Merus Nv Binding molecules that inhibit cancer growth
CN108350078A (zh) * 2015-11-03 2018-07-31 默克专利股份公司 用于提高肿瘤选择性和抑制的双特异性抗体及其用途
MA43186B1 (fr) 2015-11-03 2022-03-31 Janssen Biotech Inc Anticorps se liant spécifiquement à pd-1 et leurs utilisations
AU2017214692B2 (en) * 2016-02-06 2021-11-04 Epimab Biotherapeutics, Inc. Fabs-in-tandem immunoglobulin and uses thereof
AU2017269335B2 (en) 2016-05-26 2021-07-01 Recurium Ip Holdings, Llc EGFR inhibitor compounds
KR101985299B1 (ko) * 2016-06-03 2019-09-03 삼성전자주식회사 항-c-Met/항-Nrp1 이중 특이 항체
CN109689080A (zh) * 2016-06-21 2019-04-26 詹森生物科技公司 半胱氨酸工程化iii型纤连蛋白结构域结合分子
US11701384B2 (en) 2016-09-02 2023-07-18 The Regents Of The University Of California Methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
US11702480B2 (en) 2016-11-18 2023-07-18 The Regents Of The University Of California Engineered antibodies and uses thereof
AU2017378226A1 (en) 2016-12-14 2019-06-20 Janssen Biotech, Inc. CD8A-binding fibronectin type III domains
US10597438B2 (en) 2016-12-14 2020-03-24 Janssen Biotech, Inc. PD-L1 binding fibronectin type III domains
US10611823B2 (en) 2016-12-14 2020-04-07 Hanssen Biotech, Inc CD137 binding fibronectin type III domains
TWI723247B (zh) * 2017-02-06 2021-04-01 中央研究院 重組蛋白及其用途
JP2020511993A (ja) 2017-03-31 2020-04-23 メルス ナムローゼ フェンノートシャップ ＮＲＧ１融合遺伝子を有する細胞の処置における使用のためのＥｒｂＢ−２及びＥｒｂＢ３結合二重特異性抗体
RU2751720C2 (ru) * 2017-05-30 2021-07-16 Чонг Кун Данг Фармасьютикал Корп. Новое анти-с-мет антитело и его применение
WO2018221969A1 (en) * 2017-05-30 2018-12-06 Chong Kun Dang Pharmaceutical Corp. A novel anti-c-met antibody and use thereof
MA49846A (fr) * 2017-08-09 2020-06-17 Merus Nv Anticorps qui se lient à l'egfr et à cmet
EP3672611A4 (en) * 2017-08-25 2021-07-14 Janssen Biotech, Inc. TYPE III DOMAINS OF FIBRONECTIN BINDER FCyRII, THEIR CONJUGATES AND MULTISPECIFIC MOLECULES INCLUDING THEM
CN109912716B (zh) * 2017-12-13 2022-08-23 凯惠科技发展(上海)有限公司 一种egfr抗体及其制备方法和应用
US20190184028A1 (en) * 2017-12-14 2019-06-20 Janssen Biotech, Inc. Targeting with firbronectin type iii like domain molecules
WO2019224718A2 (en) 2018-05-24 2019-11-28 Janssen Biotech, Inc. Psma binding agents and uses thereof
CN112955137A (zh) * 2018-09-10 2021-06-11 米拉蒂治疗股份有限公司 组合疗法
AU2019338207A1 (en) * 2018-09-10 2021-04-29 Mirati Therapeutics, Inc. Combination therapies
PE20211078A1 (es) * 2018-10-22 2021-06-09 Janssen Pharmaceutica Nv Proteinas de fusion de peptido similar al glucagon 1 (glp1)-factor de diferenciacion de crecimiento 15 (gdf15) y usos de estas
JP2022509724A (ja) 2018-12-05 2022-01-24 ミラティ セラピューティクス， インコーポレイテッド 組み合わせ療法
TW202043268A (zh) * 2018-12-18 2020-12-01 美商健生生物科技公司 產生異二聚體抗體之方法
JP2022521610A (ja) * 2019-02-26 2022-04-11 ヤンセン バイオテツク，インコーポレーテツド 二重特異性抗ｅｇｆｒ／ｃ－ｍｅｔ抗体による併用療法及び患者層別化
CA3136888A1 (en) 2019-04-19 2020-10-22 Janssen Biotech, Inc. Methods of treating prostate cancer with an anti- psma/cd3 antibody
EA202193117A1 (ru) * 2019-05-14 2022-02-11 Янссен Байотек, Инк. КОМБИНИРОВАННЫЕ ТЕРАПИИ С ИСПОЛЬЗОВАНИЕМ БИСПЕЦИФИЧЕСКИХ АНТИТЕЛ К EGFR/c-MET И 3-ГО ПОКОЛЕНИЯ ИНГИБИТОРОВ ТИРОЗИНКИНАЗЫ EGFR
US11879013B2 (en) 2019-05-14 2024-01-23 Janssen Biotech, Inc. Combination therapies with bispecific anti-EGFR/c-Met antibodies and third generation EGFR tyrosine kinase inhibitors
US11850248B2 (en) 2019-05-14 2023-12-26 Yuhan Corporation Therapies with 3rd generation EGFR tyrosine kinase inhibitors
EP4031574A1 (en) 2019-09-16 2022-07-27 Regeneron Pharmaceuticals, Inc. Radiolabeled met binding proteins for immuno-pet imaging
WO2021076574A2 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Fn3 domain-sirna conjugates and uses thereof
CN114786682A (zh) 2019-10-14 2022-07-22 Aro生物疗法公司 结合cd71的纤维粘连蛋白iii型结构域
JOP20220184A1 (ar) * 2020-02-12 2023-01-30 Janssen Biotech Inc علاج مصابي السرطان ممن لديهم طفرات تخطي c-Met إكسون14
TW202207940A (zh) 2020-04-14 2022-03-01 美商健生生物科技公司 包含胺基嘧啶衍生物或其醫藥上可接受之鹽、水合物、或溶劑化物之用於經口投予之醫藥組成物
IL300854A (en) * 2020-08-25 2023-04-01 Janssen Biotech Inc Treatment of non-small cell lung cancer with EGFR mutations
AR123340A1 (es) * 2020-08-26 2022-11-23 Janssen Biotech Inc FORMULACIONES ESTABLES QUE COMPRENDEN UN ANTICUERPO BIESPECÍFICO PARA EGFR / c-MET
KR20230069958A (ko) 2020-09-14 2023-05-19 얀센 파마슈티카 엔.브이. Fgfr 억제제 조합 요법
EP4284838A2 (en) 2021-01-28 2023-12-06 Janssen Biotech, Inc. Psma binding proteins and uses thereof
WO2022189942A1 (en) 2021-03-09 2022-09-15 Janssen Biotech, Inc. Treatment of cancers lacking egfr-activating mutations
TW202309094A (zh) 2021-05-18 2023-03-01 美商健生生物科技公司 用於識別癌症患者以進行組合治療之方法
KR20240032959A (ko) * 2021-07-14 2024-03-12 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 Hgfr 및 egfr에 특이적으로 결합하는 항원-결합 분자, 및 이의 약학적 용도
CA3232216A1 (en) * 2021-10-18 2023-04-27 Tavotek Biotherapeutics (Hong Kong) Limited Anti-egfr antibodies, anti-cmet antibodies, anti-vegf antibodies, multispecific antibodies, and uses thereof
US20230183360A1 (en) * 2021-12-09 2023-06-15 Janssen Biotech, Inc. Use of Amivantamab to Treat Colorectal Cancer
TW202342057A (zh) 2022-02-07 2023-11-01 美商健生生物科技公司 用於減少用ｅｇｆｒ／ｍｅｔ雙特異性抗體治療之患者的輸注相關反應之方法
CN114740108B (zh) * 2022-03-28 2023-07-14 天津键凯科技有限公司 一种聚合物修饰抗体类药物的修饰度的测定方法
WO2024002235A1 (en) * 2022-06-29 2024-01-04 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-egfr/met antibodies and uses thereof
WO2024003837A1 (en) * 2022-06-30 2024-01-04 Janssen Biotech, Inc. Use of anti-egfr/anti-met antibody to treat gastric or esophageal cancer

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
DE3785186T2 (de) 1986-09-02 1993-07-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
WO1991003489A1 (en) 1989-09-08 1991-03-21 The Johns Hopkins University Structural alterations of the egf receptor gene in human gliomas
EP0494955B1 (en) 1989-10-05 1998-07-15 Optein, Inc. Cell-free synthesis and isolation of novel genes and polypeptides
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0531472B1 (en) 1991-03-06 2003-08-13 MERCK PATENT GmbH Humanized monoclonal antibodies
WO1993011236A1 (en) 1991-12-02 1993-06-10 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
AU5670194A (en) 1992-11-20 1994-06-22 Enzon, Inc. Linker for linked fusion polypeptides
EP0672142B1 (en) 1992-12-04 2001-02-28 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
DE69839147T2 (de) 1997-06-12 2009-02-19 Novartis International Pharmaceutical Ltd. Künstliche antikörperpolypeptide
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6472147B1 (en) 1999-05-25 2002-10-29 The Scripps Research Institute Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries
US20130226834A1 (en) 2000-04-27 2013-08-29 Networth Services, Inc. Systems and methods for determining the financial status of bonds
PT2163256E (pt) 2001-05-11 2015-11-20 Ludwig Inst For Cancer Res Ltd Proteínas de ligação específica e suas utilizações
US7595378B2 (en) * 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
JP4298498B2 (ja) * 2001-06-13 2009-07-22 ゲンマブ エー／エス 上皮成長因子受容体（ｅｇｆｒ）に対するヒトモノクローナル抗体
EP1283053A1 (en) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
JP4602614B2 (ja) 2001-09-26 2010-12-22 アイシン精機株式会社 自動車用ドア
DE60335000D1 (de) 2002-09-06 2010-12-30 Isogenica Ltd In vitro peptid-expressionsbank
EP1592713A2 (en) 2003-02-13 2005-11-09 Pharmacia Corporation Antibodies to c-met for the treatment of cancers
SI1648998T1 (sl) * 2003-07-18 2015-01-30 Amgen Inc. Specifiäťna vezavna sredstva na hepatocitni rastni faktor
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
JP2008504809A (ja) 2004-06-04 2008-02-21 ジェネンテック・インコーポレーテッド Ｅｇｆｒ突然変異
ZA200701656B (en) 2004-08-05 2008-09-25 Genentech Inc Humanized anti-cment antagonists
US20060204493A1 (en) 2004-09-02 2006-09-14 Genentech, Inc. Heteromultimeric molecules
WO2006106905A1 (ja) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha 会合制御によるポリペプチド製造方法
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
DK2076289T3 (da) 2007-04-13 2015-02-09 Dana Farber Cancer Inst Inc Fremgangsmåder til behandling af cancerresistens over for ErbB-lægemider
US20090042906A1 (en) 2007-04-26 2009-02-12 Massachusetts Institute Of Technology Methods for treating cancers associated with constitutive egfr signaling
US20110256142A1 (en) 2007-09-06 2011-10-20 Genmab A/S Novel methods and antibodies for treating cancer
US8748356B2 (en) 2007-10-19 2014-06-10 Janssen Biotech, Inc. Methods for use in human-adapting monoclonal antibodies
EP2231870A4 (en) 2007-12-19 2011-01-26 Centocor Ortho Biotech Inc SYNTHESIS PHAGE VECTORS FOR DESIGNING AND GENERATING A BANK OF PROTEIN PHAGES OR PEPTIDES HUMAN NON-ANTIBODIES BY MELTING AT PIX OF PHAGE M13
WO2009085462A1 (en) 2007-12-19 2009-07-09 Centocor, Inc. Design and generation of human de novo pix phage display libraries via fusion to pix or pvii, vectors, antibodies and methods
TW200940064A (en) 2008-03-06 2009-10-01 Genentech Inc Combination therapy with C-MET and EGFR antagonists
PE20091827A1 (es) 2008-04-11 2009-11-20 Galaxy Biotech Llc Combinacion del inhibidor hgf y el inhibidor egf para el tratamiento del cancer
BRPI0917871A2 (pt) * 2008-08-15 2017-06-20 Merrimack Pharmaceuticals Inc agente terapêutico anti-erbb3 para uso em terapia de um tumor, métodos para predizer responsividade de um tumor de um agente terapêutco anti-erbb3, para selecionar terapia anti-erbb3 para um paciente, para predizer a resposta de células ao tratamento com um agente terapêutico, para identificar um biomarcador, e para evitar administração de uma droga para câncer anti-erbb3, e, kit para predizer a resposta das células ao tratamento com um agente terapêutico
WO2010039248A1 (en) 2008-10-01 2010-04-08 Ludwig Institute For Cancer Research Methods for the treatment of cancer
CA3149920A1 (en) 2008-10-31 2010-05-06 Janssen Biotech, Inc. Fibronectin type iii domain based scaffold compositions, methods and uses
US8545839B2 (en) * 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
US20100173013A1 (en) * 2009-01-08 2010-07-08 Denis Drygin Treatment of neoplastic disorders using combination therapies
AU2010233993A1 (en) 2009-04-07 2011-09-08 Roche Glycart Ag Bispecific anti-ErbB-1/anti-c-Met antibodies
JP2012525149A (ja) 2009-04-27 2012-10-22 オンコメッド ファーマシューティカルズ インコーポレイテッド ヘテロ多量体分子を作製するための方法
JP2013503607A (ja) 2009-09-01 2013-02-04 アボット・ラボラトリーズ 二重可変ドメイン免疫グロブリンおよびその使用
DK2506871T3 (da) 2009-11-30 2017-01-02 Janssen Biotech Inc ANTISTOF-Fc-MUTANTER MED ABLATEREDE EFFEKTORFUNKTIONER
CN107739407B (zh) * 2010-03-10 2021-07-06 根马布股份公司 抗c-MEt的单克隆抗体
MX353144B (es) * 2010-04-20 2017-12-20 Genmab As Proteinas que contienen fc de anticuerpos heterodimericos y metodos para produccion de las mismas.
PT3103478T (pt) 2010-04-30 2019-07-10 Janssen Biotech Inc Composições, métodos e utilizações de domínios de fibronectinas estabilizadas
US9127319B2 (en) * 2010-06-15 2015-09-08 Alberto Bardelli MLK4 gene, a new diagnostic and prognostic marker in cancers
WO2012042026A1 (en) 2010-09-30 2012-04-05 Ablynx Nv Biological materials related to c-met
PL2635607T3 (pl) 2010-11-05 2020-05-18 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
CN104039809A (zh) * 2011-10-10 2014-09-10 希望之城公司 中间位和中间位结合抗体及其用途
WO2013063702A1 (en) 2011-11-04 2013-05-10 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
US9695228B2 (en) * 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
HUE052548T2 (hu) * 2012-11-21 2021-05-28 Janssen Biotech Inc Bispecifikus EGFR/C-MET-ellenanyagok

Also Published As

Publication number Publication date
EP3808767C0 (en) 2023-12-06
JP7397105B2 (ja) 2023-12-12
AU2021202394A1 (en) 2021-05-20
JP7019771B2 (ja) 2022-02-15
NL301173I1 (nl) 2022-05-04
EP3808767B1 (en) 2023-12-06
BR112015011717A2 (pt) 2017-08-15
HUS2200016I1 (hu) 2022-05-28
CA2893505C (en) 2023-02-21
EP2922872A4 (en) 2016-07-06
NL301173I2 (nl) 2022-06-15
EP3447069A1 (en) 2019-02-27
BR112015011717B1 (pt) 2023-12-12
PT3447069T (pt) 2020-11-13
US20140255408A1 (en) 2014-09-11
US9695242B2 (en) 2017-07-04
MX361088B (es) 2018-11-26
SI2922872T1 (sl) 2019-01-31
PE20151181A1 (es) 2015-08-19
PH12015501118A1 (en) 2016-02-01
JP2016505537A (ja) 2016-02-25
LTPA2022507I1 (lt) 2022-06-27
EP2922872B1 (en) 2018-10-10
FR22C1018I2 (fr) 2023-05-05
CA2893505A1 (en) 2014-05-30
HRP20201848T1 (hr) 2021-01-08
JP6423357B2 (ja) 2018-11-14
US9593164B2 (en) 2017-03-14
RS58192B1 (sr) 2019-03-29
EA201590985A1 (ru) 2015-11-30
PL2922872T3 (pl) 2019-03-29
CA3182876A1 (en) 2014-05-30
US20170101475A1 (en) 2017-04-13
SG11201503938VA (en) 2015-06-29
HUE052548T2 (hu) 2021-05-28
JP2024026236A (ja) 2024-02-28
JP2022062155A (ja) 2022-04-19
AU2013347962B2 (en) 2018-10-25
KR20220032654A (ko) 2022-03-15
AU2021202394B2 (en) 2024-03-07
FR22C1018I1 (fr) 2022-06-17
RS61057B1 (sr) 2020-12-31
CY1121270T1 (el) 2020-05-29
DK3447069T3 (da) 2020-11-16
NZ708352A (en) 2019-10-25
EA031184B1 (ru) 2018-11-30
MX2015006387A (es) 2015-12-03
AU2013347962A1 (en) 2015-05-28
NI201500069A (es) 2015-10-19
HUE041499T2 (hu) 2019-05-28
CY1123550T1 (el) 2022-03-24
CN104955838B (zh) 2021-02-02
PH12015501118B1 (en) 2016-02-01
UA117121C2 (uk) 2018-06-25
AU2019200441A1 (en) 2019-02-07
LT2922872T (lt) 2018-12-27
KR20240005211A (ko) 2024-01-11
CN113201073A (zh) 2021-08-03
PT2922872T (pt) 2019-01-18
KR20150087365A (ko) 2015-07-29
US20140141000A1 (en) 2014-05-22
IL238796A0 (en) 2015-06-30
EP3447069B1 (en) 2020-09-23
ES2700231T3 (es) 2019-02-14
FIC20220016I1 (fi) 2022-05-31
EP3808767A1 (en) 2021-04-21
WO2014081954A1 (en) 2014-05-30
SI3447069T1 (sl) 2021-02-26
AU2019200441B2 (en) 2021-01-28
US9580508B2 (en) 2017-02-28
JP6773746B2 (ja) 2020-10-21
JP2021006561A (ja) 2021-01-21
DK2922872T3 (da) 2019-01-02
JP2019048817A (ja) 2019-03-28
CN104955838A (zh) 2015-09-30
EP2922872A1 (en) 2015-09-30
KR102373193B1 (ko) 2022-03-10
HRP20182128T1 (hr) 2019-02-08
CL2015001356A1 (es) 2015-11-06
IL238796B (en) 2019-06-30
ES2831374T3 (es) 2021-06-08

Similar Documents

Publication Publication Date Title
HUS2200016I1 (hu) Bispecifikus EGFR/C-MET-ellenanyagok
HK1217958A1 (zh) 四價雙特異性抗體
EP2922874A4 (en) BISPECIFIC ANTIBODIES
IL235042A0 (en) Anti–fcrn antibodies
ZA201506568B (en) Anti-tnf-anti-il-17 bispecific antibodies
HK1204571A1 (en) Protease-regulated antibodies
HK1210192A1 (en) Anti-siglec-15 antibodies siglec-15
IL235059A0 (en) Anti–il–23p19 antibodies
ZA201407272B (en) Anti-baff-anti-il-17 bispecific antibodies
HK1210186A1 (en) Anti-h7cr antibodies h7cr
IL235188A0 (en) Antibodies against c-pdgf